FeesSafety
Pluang+

Johnson & Johnson raises dividend for 64th year amid strong cash flow and growth despite drug competition.

Company Fundamentals
04 Sep 2026, 16:04 WIB
24/7 Wall Street
View Source
Bullish
Johnson & Johnson raises dividend for 64th year amid strong cash flow and growth despite drug competition.

Johnson & Johnson has increased its dividend for the 64th consecutive year, paying $1.34 per share quarterly, reflecting a 3.1% raise. The company maintains a strong financial position with a payout ratio near 48%, supported by robust operating cash flow of $24.53 billion in 2025 against a $12.38 billion dividend payout. Despite competitive pressures on its drug STELARA, JNJ's innovative medicines continue to grow, with sales reaching $25.3 billion in Q2 2026 and adjusted EPS guidance raised for 2026. This steady growth and strong cash flow underpin JNJ's commitment to returning capital to shareholders, making its dividend attractive for income-focused investors.

More News (JNJ)

Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Johnson & Johnson continues to show resilience with a 64-year dividend increase streak and raised full-year revenue and earnings guidance for 2026. Despite its strong business fundamentals and leadership in pharmaceuticals and medical devices, the st...

Company Fundamentals
Bullish
1 hour ago
Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson and Pfizer are key healthcare giants with differing strategies: J&J balances drug innovation and medical devices, while Pfizer focuses on oncology and obesity treatments. J&J reported stronger revenue growth and higher net income, w...

Market News
Neutral
2 hours ago
Johnson & Johnson remains a strong dividend stock but is pricey for value investors now.

Johnson & Johnson remains a strong dividend stock but is pricey for value investors now.

Johnson & Johnson continues to lead in pharmaceuticals and medical devices, boasting a 64-year streak of dividend increases. The company recently raised its full-year revenue and earnings guidance, reflecting solid business performance. However, its ...

Company Fundamentals
Bullish
6 hours ago
Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson and Pfizer, two healthcare giants, are taking different growth paths heading into 2027. Johnson & Johnson maintains a balanced business with strong pharmaceutical and medical device segments, showing steady revenue growth and a soli...

Market News
Neutral
7 hours ago
Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

The Dow Jones Industrial Average fell nearly 950 points on Friday, entering correction territory by closing over 10% below its record high. The sell-off was driven by continued weakness in technology stocks, including a 14% drop in Nvidia after SEC a...

Bearish
10 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App